We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
-1.53%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$476M
AUM Growth
-$2.63M
Cap. Flow
+$7.22M
Cap. Flow %
1.52%
Top 10 Hldgs %
99.49%
Holding
14
New
1
Increased
3
Reduced
–
Closed
1

Top Buys

1
BBOT
BridgeBio Oncology
BBOT
+$4.87M
2
EPRX
Eupraxia Pharmaceuticals
EPRX
+$2.62M
3
GLUE icon
Monte Rosa Therapeutics
GLUE
+$1.59M
4
CMPS
Compass Pathways
CMPS
+$1.57M

Top Sells

1
CALC icon
CalciMedica
CALC
+$3.43M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.9B
$378M 79.35%
5,089,611
– –
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$2.02B
$30.8M 6.46%
1,316,806
– –
GLUE icon
3
Monte Rosa Therapeutics
GLUE
$2.07B
$25.6M 5.37%
1,555,664
+83,333
+6% +$1.59M
BCAX
4
Bicara Therapeutics
BCAX
$1.82B
$11.3M 2.38%
568,919
– –
BBOT
5
BridgeBio Oncology
BBOT
$686M
$9.11M 1.91%
1,018,018
+453,393
+80% +$4.87M
CMPS
6
Compass Pathways
CMPS
$1.67B
$7.92M 1.66%
1,432,336
+233,918
+20% +$1.57M
SRRK icon
7
Scholar Rock
SRRK
$6.33B
$3.79M 0.8%
77,031
– –
BMEA icon
8
Biomea Fusion
BMEA
$92.5M
$3.13M 0.66%
2,048,757
– –
EPRX
9
Eupraxia Pharmaceuticals
EPRX
$431M
$2.35M 0.49%
+325,000
New +$2.62M
URGN icon
10
UroGen Pharma
URGN
$1.96B
$1.94M 0.41%
108,000
– –
ACRS icon
11
Aclaris Therapeutics
ACRS
$793M
$1.63M 0.34%
434,455
– –
MRKR icon
12
Marker Therapeutics
MRKR
$21.8M
$423K 0.09%
325,370
– –
OKUR
13
OnKure Therapeutics
OKUR
$170M
$367K 0.08%
88,607
– –
CALC icon
14
CalciMedica
CALC
$11.6M
– –
-521,114
Closed -$3.43M

Similar funds

PCMC
Paragon Capital Management (Colorado) Denver, Colorado $476M AUM 23.92% 1-Year Est. Return
BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
JSC
Jackson Square Capital San Francisco, California $477M AUM 78.87% 1-Year Est. Return
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return

Aisling Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Aisling Capital Management held 14 positions worth $476M, down 0.55% from $479M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Aisling Capital Management's Q1 2026 filing shows 1 new, 3 increased and 1 closed positions. Its largest new stake was Eupraxia Pharmaceuticals: 325,000 shares worth $2.35M. The largest sale was CalciMedica, an estimated $3.43M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management's largest Q1 2026 buy was Eupraxia Pharmaceuticals: 325,000 shares worth $2.35M.
  • Aisling Capital Management added most to BridgeBio Oncology in Q1 2026, an estimated $4.87M increase.
  • Aisling Capital Management fully exited CalciMedica in Q1 2026, selling an estimated $3.43M.
  • Aisling Capital Management's ten largest holdings make up 99% of its $476M portfolio in Q1 2026.
  • Aisling Capital Management opened 1 new position and closed 1 in Q1 2026.
  • Aisling Capital Management's portfolio value fell 0.55% quarter-over-quarter to $476M.

Based on Aisling Capital Management's 13F filing for Q1 2026, filed 5 May 2026.